News & Updates

Oxaliplatin stop-and-go strategy provides similar PFS, OS vs 1st-line SoC in pancreatic cancer

11 Aug 2021 by

An oxaliplatin stop-and-go strategy of maintenance treatment with leucovorin plus fluorouracil in patients with metastatic pancreatic cancer controlled after 4 months of standard first-line fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) provides comparable progression-free survival (PFS) and overall survival (OS) vs 6 months of FOLFIRINOX, results of the phase II PANOPTIMOX-PRODIGE 35 trial have shown.

Oxaliplatin stop-and-go strategy provides similar PFS, OS vs 1st-line SoC in pancreatic cancer

11 Aug 2021

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021 by

Exposure to chemotherapy in the first 12 weeks of pregnancy may be associated with an increased risk of major congenital malformations in offspring, a recent study showed.

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Use of cetuximab in combination with afatinib for the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutation does not appear to improve outcomes as compared with afatinib alone, according to the results of a phase II trial.

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021 by

The likelihood of pT3* or higher tumours and node-positive disease found at the time of radical prostatectomy (RP) for prostate cancer (PCa) was greater during the COVID-19 pandemic than it was before, an expert reported at EAU21.

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021 by

Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Young women with breast cancer who are receiving treatment with modern chemotherapy regimens are likely to develop short episodes of treatment-related amenorrhea, but the vast majority of them will maintain or regain menstrual function, a study has found.

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

A multitarget faecal immunochemical test (mtFIT) is more accurate than conventional FIT in detecting advanced neoplasia due to an increased detection of advanced adenomas, according to a study.

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

FUT1-triggered signalling pathway underlies HCC drug resistance and tumour recurrence

30 Jul 2021 by

Results of a recent immunology study by researchers from the University of Hong Kong (HKU) have revealed fucosyltransferase 1 (FUT1) as the key component in protein kinase RNA-like endoplasmic reticulum kinase (PERK)–mediated signalling pathway underlying cancer stemness in hepatocellular carcinoma (HCC), and in driving drug resistance and tumour recurrence.

FUT1-triggered signalling pathway underlies HCC drug resistance and tumour recurrence

30 Jul 2021

Complementary or alternative medicine commonly used in childhood cancer survivors

30 Jul 2021 by

A study by researchers from the Chinese University of Hong Kong (CUHK) finds a high prevalence of use of complementary or alternative medicine (CAM) among childhood cancer survivors in Hong Kong, with potential CAM-drug interactions detected in nearly a third of those on long-term medications. Future studies focusing on behaviour and motivations of survivors for CAM use are suggested.

Complementary or alternative medicine commonly used in childhood cancer survivors

30 Jul 2021

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

Alcohol consumption does not seem to substantially impact population occurrence rates of pancreatic cancer, a recent Taiwan study has found. This null effect seems to hold even among people who are genetically susceptible to the carcinogenicity of alcohol.

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

News & Updates

Filter by Specialty:

Specialty:

Oxaliplatin stop-and-go strategy provides similar PFS, OS vs 1st-line SoC in pancreatic cancer

Oxaliplatin stop-and-go strategy provides similar PFS, OS vs 1st-line SoC in pancreatic cancer

Timing of chemo during pregnancy may affect congenital malformation risk

Timing of chemo during pregnancy may affect congenital malformation risk

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Has COVID-19 changed the pathological outcomes in prostate cancer?

Has COVID-19 changed the pathological outcomes in prostate cancer?

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Treatment-related amenorrhea common in young breast cancer patients

Treatment-related amenorrhea common in young breast cancer patients

Multitarget FIT better than standard test for colorectal cancer screening

Multitarget FIT better than standard test for colorectal cancer screening

FUT1-triggered signalling pathway underlies HCC drug resistance and tumour recurrence

FUT1-triggered signalling pathway underlies HCC drug resistance and tumour recurrence

Complementary or alternative medicine commonly used in childhood cancer survivors

Complementary or alternative medicine commonly used in childhood cancer survivors

Taiwan study: No link between drinking and pancreatic cancer

Taiwan study: No link between drinking and pancreatic cancer